Page 8 - Nasdaq Mltx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq mltx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Mltx Today - Breaking & Trending Today

Wedbush Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $61.00

MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its target price upped by Wedbush from $33.00 to $61.00 in a research note issued to investors on Tuesday morning, The Fly reports. Wedbush also issued estimates for MoonLake Immunotherapeutics’ FY2027 earnings at ($1.45) EPS. Several other research analysts have also recently weighed in on the company. Guggenheim […] ....

Bihua Chen , Moonlake Immunotherapeutics , Citadel Advisors , Cantor Fitzgerald , Century Group , Hermes Inc , Pricet Rowe Associates Inc , Free Report , Moderate Buy , Nasdaq Mltx , Boost Price Target ,

SVB Securities Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $56.00

MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its price objective raised by SVB Securities from $28.00 to $56.00 in a research note issued to investors on Monday, The Fly reports. Several other analysts have also recently commented on the stock. HC Wainwright increased their price target on shares of MoonLake Immunotherapeutics from $28.00 to $30.00 […] ....

Moonlake Immunotherapeutics , Bihua Chen , Citadel Advisors , Cantor Fitzgerald , Pricet Rowe Associates Inc , Millennium Management , Free Report , Moderate Buy , Pricet Rowe Associates , Nasdaq Mltx , Boost Price Target , Svb Securities ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) PT Raised to $56.00

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) had its price objective lifted by investment analysts at SVB Securities from $28.00 to $56.00 in a research note issued on Monday, The Fly reports. SVB Securities’ price target points to a potential upside of 21.87% from the company’s previous close. MLTX has been the topic of several other […] ....

United States , Moonlake Immunotherapeutics , Century Group , Geode Capital Management , Cantor Fitzgerald , Renaissance Technologies , Goldman Sachs Group Inc , Ensign Peak Advisors Inc , America Corp , Get Rating , Capital Management , Peak Advisors Inc , Goldman Sachs Group , Nasdaq Mltx , Boost Price Target , Svb Securities ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $25.63 Consensus Target Price from Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price […] ....

United States , Moonlake Immunotherapeutics , Cantor Fitzgerald , Citigroup Inc , Geode Capital Management , America Corp , Century Group , Pricet Rowe Associates Inc , Get Rating , Capital Management , Pricet Rowe Associates , Nasdaq Mltx ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns Equal Weight Rating from Analysts at Barclays

Barclays assumed coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in a research note issued to investors on Thursday morning, The Fly reports. The brokerage issued an equal weight rating and a $28.00 target price on the stock. MLTX has been the subject of a number of other reports. HC Wainwright boosted their […] ....

United States , Moonlake Immunotherapeutics , America Corp , Century Group , Moonlake Immunotherapeutics Company Profile , Citigroup Inc , Geode Capital Management , Cantor Fitzgerald , Pricet Rowe Associates Inc , Get Rating , Moderate Buy , Capital Management , Pricet Rowe Associates , Nasdaq Mltx , Initiated Coverage , Barclays Plc ,